Aldeyra says its can­di­date won in chron­ic cough PhII, set­ting stage for bout with Mer­ck, GSK

Aldeyra said that its ther­a­py re­duced cough fre­quen­cy in pa­tients with chron­ic cough in a Phase II study, as drug­mak­ers fo­cus on de­vel­op­ing treat­ments for a con­di­tion with no ap­proved ther­a­pies in the US or Eu­rope.

The biotech re­vealed topline da­ta Tues­day morn­ing for the drug, an oral RASP (re­ac­tive alde­hyde species) mod­u­la­tor, in a Phase II crossover tri­al. The pri­ma­ry end­point of the tri­al was safe­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER